Category Archives: Stem Cell Therapy

Monalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.

Monalisa Ghosh, MD, a clinical assistant professor at the University of Michigan, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.

These products are promising in many ways and provide several advantages, including a decreased manufacturing time, Ghosh says. Experts in the field can request and receive off-the-shelf CAR T-cell products from a bank, she explains.This eliminates the need to wait for patient cell collection, which puts the patient at some degree of risk, and decreases the manufacturing time that ordinarily takes several weeks. The decreased treatment timeline can also be beneficial to patients with rapidly progressive disease, Ghosh notes.

However, challenges exist with this therapy, as allogenic cells may cause certain adverse effects, such as a graft-versus-host reaction that is similar to reactions observed with stem cell transplantation, Ghosh says. Currently, certain methods of T-cell receptor engineering may be able to mitigate this risk, she adds.Additionally, some hosts may reject the cells, a possibility that has been observed in early studies, wherein cells have not demonstrated long-term persistence.It may be possible to overcome this through multiple cell infusions, Ghosh notes.

Overall, the accessibility of off-the-shelf CAR T-cell products to a large group of patients with multiple myeloma appears promising, Ghosh concludes.

Continued here:
Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in Myeloma June - OncLive

Canine Stem Cell Therapy Market research report documents in-depth analysis of the global and the regional markets on various parameters that drives the market. Market analysis, factual data, and market forecasts are few areas covered in this report. This report also outlines the growth of the markets over the span of years, the changing dynamics of the markets, rules, and laws that govern the regional and international markets, revenue generation and production cost variations, and much more.

The Canine Stem Cell Therapy was valued at 48500 Billion US$ in 2021 and is projected to reach 59700 Billion US$ by 2025, at a CAGR of 6.3% during the forecast period.

The non-invasive stem cell obtaining procedure augmented the possibility of accomplishing high-quality cells, and the lower price of therapy coupled with a high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

Top Key Players Profiled in This Report:VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics,

Ask for a Sample Copy of This:

https://www.theresearchinsights.com/request_sample.php?id=240368&mode=RON

What this research report offers:

The purpose of this study is to define the overview of the Rising Demand for Canine Stem Cell Therapy Market with respect to market size, shares, sales patterns, and pricing structures. Primary and secondary research refer collect the desired data of the target market. Different global regions such as North America, Latin America, Asia-Pacific, Africa, and the Middle East are examined to evaluate the facts about productivity.

Get a Discount on This:

https://www.theresearchinsights.com/request_sample.php?id=240368&mode=RON

The key questions answered in the report:

Which are the global opportunities for expanding the Rising Demand for Canine Stem Cell Therapy Market?

If You Have Any Query, Ask Our

https://www.theresearchinsights.com/checkout?id=240368&mode=RON

About us:

The Research Insights is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. The Research Insights offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials, and much more.

Contact us:

Robin

Sales manager

Contact number:

APAC +91-996-067-0000

UK +44-753-718-0101

USA +1-312-313-8080

sales@theresearchinsights.com

http://www.theresearchinsights.com

See the original post:
Canine Stem Cell Therapy Market 2021 Analysis and Precise Outlook Therapeutics, Medivet Biologics, Okyanos The Courier - The Courier

Michael Bishop, MD, a professor of medicine and director of Hematopoietic Stem Cell Transplantation Program at The University of Chicago Medicine, discussesthe different settings where chimeric antigen receptor (CAR) T-cell therapy are used.

Bishop thinks CAR T-cell therapy made a significant impact upon patient care. CAR T cells are indicated for 3 main groups of patients. The first is for non-Hodgkin lymphoma and for pediatric and young adult acute lymphoblastic leukemia (ALL), which has FDA-approved agents. More recent approvals have been for patients with mantle cell lymphoma. Physicians are waiting for what they expect to be the first indication for CAR T-cell therapy in multiple myeloma.

Starting with ALL for the pediatric population, CAR T cells have been a game changer, according to Bishop. These young patients have median overall survivals of less than 6 months, but the high response rates with CAR T are enabling them to potentially go on to an allogeneic stem cell transplant and in some cases, be free of disease.

In the non-Hodgkin lymphoma setting, there are now 3 products indicated for advanced B-cell non-Hodgkin lymphoma, which is significant for patients with totally refractory disease. There is this therapeutic option that is potentially curative. Bishop says investigators are seeing patients out to 5 years without any further therapy after receiving CAR T cells.

View original post here:
CAR T Cells Have Reshaped the Hematologic Cancer Landscape - Targeted Oncology

Long-term follow-up data from the KarMMa trial found that treatment with the chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel (ide-cel; formerly bb2121; Abecma), continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma, according to a presentation presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.1

The favorable benefit risk profile of ide-cel, regardless of the number of prior lines of therapy, supports its role as a treatment option for heavily pretreated relapse refractory multiple myeloma, Larry D. Anderson, MD, PhD, associate professor, UT Southwestern Medical Center, said during a presentation of the poster.

At the December 21, 2020, data cutoff, the median follow-up was 24.8 months (range, 1.7-33.6).

Overall response rate (ORR) was 73% in the overall population, including a 33% complete response rate (CRR; complete response [CR] or stringent complete response [sCR]), 20% with a very good partial response (VGPR), and 20% who had a partial response (PR). ORR rates were 50%, 69%, and 81%, respectively, across the 150, 300, and 450 million CAR T cell-dose arms, including CR/sCR rates of 25%, 29%, and 39%.

Of note, ORR did not vary by the number of prior lines of therapy received. For those who received 3 prior lines of therapy (n = 15), the ORR was 73%, including a CRR of 53% and VGPR of 20%, compared with an ORR of 73% in those who received 4 (n = 112) lines of therapy, including a CRR of 30%, VGPR of 23%, and PR of 20%.

Median duration of response (DOR) was 10.9 months (95% CI, 9.0-11.4), including 9.9 months for the 300 million CAR T cells-dose arm and 11.3 months for the 450 million CAR T cells-dose arm -dose arm. Median DOR was 21.5 months in patients who experienced a CR or sCR. Median DOR by response were 21.5 months (95% CI, 12.5 to not estimable [NE]) among those who experienced a CR, 10.4 months (95% CI, 5.1-12.2) for those with VGPR, and 4.5 months (95% CI, 2.9-6.7) in those with PRs.

Moreover, the rate of event-free 24-month DOR appeared to be similar in patients who received 3 or 4 or more lines of therapy. For those who received 3 lines of prior therapy, median DOR was 8.0 months (95% CI, 3.3-11.4), compared with 10.9 months (95% CI, 9.2-13.5) in those who received 4 or more lines of therapy.

Median progression-free survival (PFS) was 8.6 months (95% CI, 5.6-11.6) across all target doses, including 5.8 months for the 300 million CAR T cells-dose arm and 12.2 months for the 450 million CAR T cells-dose arm -dose arm. Similarly, median PFS was similar among those who previously received 3 lines of therapy, compared with 4 or more prior lines of therapy (8.6 months (95% CI, 2.9-12.1) vs 8.9 months (95% CI, 5.4-11.6)]

The median time to first response was 1 month (range, 0.5-8.8), with a median time to CR of 2.8 months (range, 1.0-15.8).

Median overall survival (OS) was 24.8 months (95% CI, 19.9-31.2), including a median OS of 22.0 months (95% CI, 10.-NE) in those who received 3 lines of prior therapy and 25.2 months (95% CI, 19.9-NE) in those who received 4 or more lines of prior therapy. Moreover, OS was 20 months or longer across several key high-risk subgroups, including those aged 65 or older (21.7 months; 95% CI, 17.1-31.2), those with extramedullary disease (20.2 months; 95% CI, 15.5-28.3), and those with triple refractory disease (21.7 months; 95% CI, 18.2-NE).

In regards to safety, cytokine release syndrome (CRS) and neurotoxicity were similar, regardless of prior lines of therapy received, and were mostly low grade. In total, 85% and 18% of the overall population experienced at least 1 CRS or neurotoxicity event, respectively.

The safety profile of ide-cel was consistent with long-term follow-up, with similar rates of infections and secondary primary malignancies, and no unexpected gene therapy related toxicities were observed. The most common grade 3 to 4 adverse events (AEs) in the overall population were neutropenia (89%), anemia (61%), thrombocytopenia (52%), leukopenia (39%), lymphopenia (27%), and infections (27%).

Long-term results from the KarMMA trial continue to demonstrate frequent, deep, and durable responses in heavily pretreated patients with [relapsed/refractory multiple myeloma], the study authors write in the poster. ORR, CRR, DOR, and PFS were consistent with previous reports and patients received similar benefit regardless of the number of prior lines of therapy.

In his presentation, Anderson presented data on long-term efficacy and safety following treatment with ide-cel in the pivotal phase 2 KarMMa trial (NCT03361748)-including overall data and by prior line of therapy that patients had received (3 vs 4), since the FDA label is requiring at least 4 prior lines, and this study only required 3, he added.

In total, 140 patients who had received at least 3 prior lines of therapy for multiple myeloma including an IMiD, a PI, and an anti-CD38 antibody and were refractory to their last treatment regimen, were enrolled in the study. However, only 128 patients received infusion with ide-cel.

Patients were treated with ide-cel across the target dose range of 150 (n = 4), 300 (n = 70), and 450 (n = 54) million CAR T cells.

ORR served as the primary end point of the study. Secondary end points included CRR, safety, DOR, PFS, OS, pharmacokinetics, minimal residual disease, quality of life, and health economics and outcomes research.

At baseline, the median patient age was 61 years (range, 33-78) and patients had a median of 6 years (range, 1-18) since their diagnosis. A majority of the patients were male (59%), had high tumor burden (51%), B-cell maturation antigen (BCMA) expression 50% at screening (85%), ECOG performance status of 1 (53%), and Revised International Staging System disease stage of II (70%). Thirty-five percent of patients had high-risk features.2

The median number of prior therapies was 6 (range, 3-16) and 94% had previously undergone at least 1 autologous hematopoietic stem cell transplant (94%). Eighty-eight percent of patients required bridging therapy. Eighty-nine percent of patients had double-refractory disease, 84% were triple-refractory, and 26% were penta-refractory.

Patients who had received 3 prior lines of therapy had similar baseline characteristics, compared with those who received 4 prior lines, including differences in extramedullary disease, high-risk cytogenetics, prior refractoriness, and time since the initial diagnosis to screening.

Patients with relapsed/refractory multiple myeloma previously exposed to immunomodulatory agents, protease inhibitors, and anti-CD38 antibodies have poor outcomes with subsequent therapy using previously approved regimens, with expected response rates in the 26% to 31% range, PFS in the 2- to 4-month range, and overall survival less than 9 months, Anderson explained.

However, the BCMA-directed CAR T-cell therapy previously demonstrated favorable tolerability with deep, durable responses in patients who were heavily pretreated with relapsed/refractory multiple myeloma.2 As a result, the FDA approved the agent for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody, representing the first BCMAdirected CAR T-cell therapy approved.3

The study authors noted that ide-cel is being explored in ongoing clinical trials, including the following:

Read the original post:
In Some Heavily Pretreated Patients with R/R MM Ide-Cel Continues to Show Deep and Durable Responses - Targeted Oncology

Combination therapy with ponatinib (Iclusig) and blinatumomab (Blincyto) induced a complete response in all patients with Philadelphia chromosome (Ph)positive acute lymphocytic leukemia (ALL) who were treated on a phase 2 study (NCT03263572), according to a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.1

The chemotherapy-free, hematopoietic stem cell transplant (HSCT)sparing regimen for patients receiving systemic therapy in the first-line (n = 20) led to a complete response (CR) rate or pathologic CR rate of 100%, while patients with relapsed/refractory Phpositive ALL had a rate of 89%. Moreover, patients in the frontline Phpositive cohort had a major molecular response (MMR) of 100% and a complete molecular response (CMR) of 85%.

The combination of ponatinib and blinatumomab is safe and effective in Ph-positive ALL, Nicholas James Short, MD, an assistant professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, said during an oral presentation of the data. Overall, the novel chemotherapy-free combination of ponatinib and blinatumomab appears to be a promising regimen in both frontline and relapsed/refractory Ph-ALL, as well as in chronic myeloid leukemia in lymphoid blast phase [CML-LBP]. Given the particularly favorable outcomes of newly diagnosed patients with frontline, Ph-positive ALL who were not transplanted in first remission, these data suggest that this regimen may serve as an effective transplant-sparing regimen in this population.

Chemotherapy plus a TKI has become the standard of care in newly diagnosed Ph-positive ALL, with first- and second-generation TKIs yielding 5-year overall survival (OS) rates of approximately 35% to 50%.2-4 Moreover, while ponatinib has yielded promising activity in patients with T315I mutations, which are present in up to 75% of patients at relapse,5 blinatumomab has demonstrated efficacy as a monotherapy in the relapsed/refractory setting, and in combination with dasatinib in newly diagnosed patients.6,7

The trial enrolled patients with newly diagnosed or relapsed/refractory Ph-positive ALL, as well as lymphoid accelerated or blast phase CML. Patients who had previously received 1 to 2 courses of chemotherapy with or without a TKI were able to enroll in the newly diagnosed cohort. Additionally, patients needed to be over 18 years of age, with a ECOG performance status of 0-1, and adequate hepatic function in order to enroll.

Patients with uncontrolled or active cardiovascular disease, including a history of myocardial infarction, cardiovascular accident, or revascularization within 3 months; congestive heart failure with reduced left ventricular ejection fraction; atrial of ventricular arrhythmia; a history of arterial or venous thromboembolism; or uncontrolled hypertension were not able to enroll on the study. Additional exclusion criteria included significant central nervous system (CNS) pathology with the exception of CNS leukemia.

Patients received a 30 mg induction dose of ponatinib and a standard dose of blinatumomab on a 4 weeks on, 2 weeks off schedule. From there, patients received up to 4 consolidation cycles of the regimen followed by maintenance ponatinib for 5 years, the dose of which decreased to 15 mg daily once patients achieved a CMR. All patients were given 12 doses of intrathecal chemotherapy with an altering administration of cytarabine and methotrexate.

The primary of end point of the trial was CMR rate in the frontline cohort, and CR/pathologic CR rate in the relapsed/refractory setting. Key secondary end points included event-free survival (EFS), OS, and safety.

To date, 20 frontline patients have been treated, 10 with relapsed/refractory disease, and 5 with CML-LBP, Short explained. The median age of the frontline cohort was 62 years [range, 34-83]. Among the 10 patients with relapsed/refractory Ph-positive ALL, 1 was primary refractory to [a] previous regimen, 4 were treated in first salvage, and 5 in second or later salvage. Among the 5 patients with CML-LBP, 3 had not received any prior therapy for blast phase disease, 1 was treated in first salvage, and 1 in second salvage.

Additional data indicated that the cohort of patients with CML-LBP had a CR or pathologic CR rate of 100%, as well as an MMR rate of 60%, and CMR rate of 40%. Moreover, the relapsed/refractory cohort achieved a rate of 88% in both MMR and CMR. In total, the overall patient population had a CR or pathologic CR rate of 96%, an MMR rate of 91%, and a CMR rate of 79%. No patients were reported to have an early death while on the study.

After the first cycle of treatment, the frontline ALL cohort had a CMR rate of 58%, an MMR rate of 26%, and 16% did not experience a response. Moreover, 75% of patients in the relapsed/refractory ALL cohort, and 20% in the CML-LBP cohort had a CMR after the first cycle, while 25% and 80% of patients from both cohorts did not respond, respectively.

Of the patients who experienced a CR or pathologic CR in the frontline ALL arm (n = 20), 1 died following CR due to post-procedural bleeding and hypovolemic shock, while 19 continue to experience ongoing responses without the need for stem cell transplantation. Notably, no patients in this have relapsed within 6 months.

In the relapsed/refractory ALL cohort, of the patients who responded (n = 9), 4 went on to receive HSCT, 1 of whom relapsed and died. Another patient relapsed and developed T315I and E255V mutations at relapse. Overall, 3 patients from this cohort are experiencing an ongoing response without the need for HSCT, while 1 patient died off study due to unknown causes.

In the CML-LBP arm, 2 responders (n = 5) relapsed, one of whom developed myeloid blast phase disease but is currently alive and in remission, while the other developed L248V and Y253H mutations at relapse but is currently alive and in remission following HSCT. Additionally, 3 patients continue to experience an ongoing response without HSCT.

After a median follow up of 12 months, the overall patient population is estimated to have 1- and 2-year EFS of 76% and 70%, respectively. Moreover, the estimated 1-year and 2-year OS were 93% and 80%, respectively. Notably, the relapsed/refractory AML cohort had an estimated 1- and 2-year EFS of 61% and 41%, respectively, as well as an estimated 1- and 2-year OS of 80% and 53%, respectively. Additionally, the CML-LBP arm had 60% estimated EFS rate at 1 and 2 years, respectively, as well as a 100% estimated 1- and 2-year rate.

Notably, there were no grade 4 or higher adverse effects (AEs) reported on the study. Common grade 3 AEs related to ponatinib in patients with ALL included elevated lipase (6%), alanine aminotransferase increase (ALT; 3%), cerebrovascular ischemia (3%), hypertension (3%) pancreatitis (3%), and deep vein thrombosis (3%). Grade 2 AEs included rash (11%), ALT increase (3%), and cerebrovascular ischemia (3%) and grade 1 AEs included rash (11%) and ALT increase (3%).

Although most AEs related to blinatumomab were grade 1 or 2 in patients with ALL, 1 patient developed grade 3 encephalopathy that was resolved by corticosteroids and treatment interruption, according to Short. Common grade 2 AEs included cytokine release syndrome (6%) and tremors (3%), as well as 1 patient who developed grade 1 tremors.

References

1. Short NJ, Kantarjian H, Konopleva MY, et al. Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract 7001.

2. Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653-651. doi:10.3324/haematol.2014.118588

3. Ravandi F, OBrien S, Cortes J, et al. Long-term follow-up of phase II study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158-4164. doi:10.1002/cncr.29646

4. Rousselot P, Coud MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosomepositive ALL. Blood. 2016;126(6):774-782. doi:10.1182/blood-2016-02-700153

5. Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5(12):e618-e627. doi:10.1016/S2352-3026(18)30176-5

6. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795-1802. doi:10.1200/JCO.2016.69.3531

7. Fo R, Bassan R, Vitale A, et al. Dasatinibblinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613-1623. doi:10.1056/NEJMoa2016272

Read more:
HSCT-Sparing, Chemotherapy-Free Treatment of Ph+ ALL With Ponatinib/Blinatumomab Leads to 100% CR Rate - Cancer Network

In patients with relapsed/refractory diffuse large B-cell lymphoma treated with the triplet combinaton of polatuzumab vedotin (Polivy), rituximab and lenalidomide, therapy was considered to be safe and effective, according to data presented at the 2021 ASCO Annual Meeting.

In this first report of a triplet combination of polatuzumab, rituximab and lenalidomide, the triplet combination showed notable efficacy in a challenging-to-treat relapsed and refractory diffuse large B-cell lymphoma population, said Catherine S.M. Diefenbach, MD, associate professor of medicine, translational director of hematology and director of clinical lymphoma at Perlmutter Cancer Center at NYU Langone Health, during the virtual presentation.

In this phase 1b/2 trial, researchers analyzed the safety of this combination in 57 patients (median age, 71 years; 67% men) with relapsed/refractory diffuse large B-cell lymphoma, were ineligible for or failed prior autologous stem cell transplantation and were treated with at least one prior anti-CD20-containing chemo-immunotherapy regimen. Efficacy of the treatment was assessed in 49 patients (median age, 72 years; 63% men).

The median age was 71, as is typical for this lymphoma, but the age range was from between 28 and 92 years, Diefenbach said.

Most patients in the safety and efficacy groups (86% and 84%, respectively) had stage 3 to 4 disease, nearly a quarter had two lines of therapy (28% and 27%) and nearly a third had three or more lines of therapy (33% and 31%). In addition, some patients underwent previous CAR T-cell therapy (5% and 6%, respectively) or prior bone marrow transplant (11% and 12%).

At induction, all patients received induction during 6 28-day cycles with 1.8 mg/kg of intravenous polatuzumab vedotin, 375 mg/m2 of intravenous rituximab and either a dose escalation of oral lenalidomide (between 10 mg and 20 mg) or the recommended daily dose of the drug on days 1 through 21. Patients who responded to the treatment at the end of induction received 6 months consolidation of 10 mg of lenalidomide (days 1 through 21, monthly) and 375 mg/m2 of rituximab (day 1 every 2 months).

Primary endpoints for this trial included the safety and tolerability of this triplet combination, in addition to complete response rates at the end of induction as assessed by positron emission tomography (PET) scans. Follow-up was conducted for a median of 9.7 months in the safety population and for 9.5 months in the efficacy population.

In the safety population, 75% of patients experienced grade 3 to 4 adverse events, with the most common including neutropenia (58%), thrombocytopenia (14%) and infections (14%). Adverse events led to 26% of patients undergoing a lenalidomide dose reduction and 67% had treatment interruption. One grade 5 adverse event related to the treatment neutropenic sepsis was reported.

The additional (adverse events) were not considered related to study drug, Diefenbach said. For example, a patient who had a fatal gastric hemorrhage who had been enrolled but not yet treated, and a patient with COVID-19 who contracted this disease 167 days after his last dose of the study therapy.

In the efficacy population, the overall response rate was 39% with a complete response rate of 29%. Ten percent of patients had a partial response. Median progression-free survival for the entire population was 6.3 months (95% CI, 4.5-9.7) with a median duration of remission of 8.1 months (95% CI, 4.7-not evaluated) and a median overall survival of 10.9 months (95% CI, 10.9-not evaluated).

However, for the patients who obtained a (complete response) this is 13 patients who were evaluable, the median progression-free survival at 9 months had not been reached, nor has the median overall survival, Diefenbach said. Nearly all patients remain in complete remission.

Additional follow-up is needed to assess the impact of consolidation therapy on the duration of long-term response, Diefenbach said. In summary, the triplet combination of polatuzumab, rituximab and lenalidomide represents a potential novel regimen for patients with transplant-ineligible relapsed and refractory diffuse large B-cell lymphoma and is worthy of further study.

Reference

Magid Diefenbach CS, Abrisqueta P, Gonzalez-Barca E, et al. Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial. J Clin Oncol. 2021;39(suppl 15):Abstract 7512.

Originally posted here:
Polatuzumab With Rituximab and Lenalidomide Shown Safe and Effective for Relapsed/Refractory DLBCL - Targeted Oncology

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Marketresearch report has set a bench-marking example for such a vibrant market that explores several recommendations and practical growth strategies in relation to the market. The chapter on the competitive landscape is presented well in the research report and is analyzed based on the tools such as Porters five forces analysis. This market research document produced covers numerous growth prospects in recent times with linkage in the coming decades. The assumptions are made here by the panels and key vendors. The business research report on a serious note focuses on the several analysis viewpoints, market rankings, industry key points, and business profiles that integrate together and form a platform. The research provides benefits to identify market opportunities and the latest trends. This market report covers a wide spectrum across geography coupled with key segments of the industry that assist the competitors to get a glimpse of the trends of the market.This general market measure is used as a part of the top-down procedure to assess the sizes of other individual markets through percentage parts from auxiliary sources catalogs, databases, and primary research.

Autologous stem cell and non-stem cell based therapies market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 121.68 billion by 2027 growing at a CAGR of 3.75 % in the above-mentioned forecast period. The introduction of novelautologousstem cell based therapies inregenerativemedicine will help in driving the growth of the autologous stem cell and non-stem cell based therapies market.

Get Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at (AVAIL UP-TO 30% OFF) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Reduction in transplant subjected risks and prevalence ofcancerand diabetes in all age groups will likely to accelerate the growth of the autologous stem cell and non-stem cell based therapies market in the forecast period of 2020-2027. On the other hand, growing geriatric population will further boost various opportunities that will lead to the growth of the autologous stem cell and non-stem cell based therapies market in the above mentioned forecast period.

Some of the Key Players/Manufacturers Involved in the Market are:

Market Segmentation:

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market, By Product (Blood Pressure (BP) Monitoring Devices, Pulmonary Pressure Monitoring Devices, Intracranial Pressure (ICP) Monitoring Devices), Applications (neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, Cardiovascular Diseases), End User (Hospitals And Ambulatory Surgical Center), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2027

Autologous stem cell and non-stem cell based therapies market is segmented on the basis of product, applications and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

According to Data Bridge Market Research the autologous stem cell and non-stem cell based therapies market in developing regions is witnessing a growth in terms of its adoption rate, due to rising ageing population, availability of novel autologous stem cell based therapies in regenerative medicine, growing popularity of cosmetic surgery and increasing R&D investment.

Now the question is which are the regions that autologous stem cell and non-stem cell based therapies market players should target? Data Bridge Market Research has estimated market leaders to target North America developing regions to help them in attaining better volume of revenue generation.

Autologous stem cell and non-stem cell based therapies market is becoming more competitive every year with cancer & tumors currently being the largest market application for the forecast period of 2018 to 2025. Data Bridge Market Researchs new report highlights the major growth factors and opportunities in the autologous stem cell and non-stem cell based therapies market.

Get Complete Details with TOC For Free @ https://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Autologous stem cell and non-stem cell based therapies market is analysed and market size insights and trends are provided by country, product, applications and end user as referenced above.

The countries covered in the autologous stem cell and non-stem cell based therapies market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

North America dominates the autologous stem cell and non-stem cell based therapies market due to minimization of risks associated with the therapy, ability to treat a large number of infectious diseases while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are some of the other factor which is driving the regions.

Autologous stem cell and non-stem cell based therapies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to autologous stem cell and non-stem cell based therapies market.

Table Of Content::

Section 01: EXECUTIVE SUMMARY

Section 02: SCOPE OF THE REPORT

Section 03: RESEARCH METHODOLOGY

Section 04: MARKET LANDSCAPE

Market environment

Market attributes

Market division examination

Section 05: PIPELINE ANALYSIS

Pipeline examination

Section 06: MARKET SIZING

Market definition

Market estimating

Market size and conjecture

Section 07: FIVE FORCES ANALYSIS

Section 08: MARKET SEGMENTATION

Division

Correlation

Market opportunity

Section 09: CUSTOMER LANDSCAPE

Section 10: REGIONAL LANDSCAPE

Section 11: DECISION FRAMEWORK

Section 12: DRIVERS AND CHALLENGES

Market drivers

Market difficulties

Section 13: MARKET TRENDS

Section 14: VENDOR LANDSCAPE

Outline

Scene disturbance

Section 15: VENDOR ANALYSIS

Sellers covered

Seller arrangement

Market situating of sellers

Region & Countries (Customizable):

More Information Related to TOC, Tables, and Figures Can Be Provided

Coronavirus can influence the worldwide economy in three principal ways: by straightforwardly influencing creation and request, by making store network and market disturbance, and by its monetary effect on firms and monetary business sectors. The episode of COVID-19 has welcomed impacts on numerous viewpoints, similar to flight undoings travel boycotts and isolates cafs shut all indoor occasions confined more than forty nations highly sensitive situation proclaimed monstrous easing back of the Vaccine market unpredictability falling business certainty, developing frenzy among the populace, and vulnerability about future.

Covid-19 Impact Analysis @ https://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Advantages of Buying the Report:

Our report is additionally known for its information exactness and granular market investigation

A total image of the serious situation of the at-home testing units market is portrayed by this report.

The broad range of investigation in regards to the significant headways

It likewise gives a total evaluation of things to come market and the changing business sector situation.

Study the market techniques that are being received by your rivals and driving associations.

Key Points Covered in Table of Content:

The report is essentially fragmented into a few key locales, import, fare, income, and piece of the pie and development pace of Microalgae in these areas, from 2021 to 2028, covering:

Presentation: It incorporates the goals and extent of the examination and gives features of key market fragments and players covered.

Leader Summary: It covers industry patterns with high spend significant time in market use cases and top market patterns, piece of the pie by locales, and Microalgae Market size and development by areas.

Central members: Here, the report centers around consolidations and acquisitions, developments, examination of vital participants, establishment date of organizations, and territories served, detailing base, and income of vital participants.

Breakdown by Market Segmentation: This segment gives insights regarding market size by item and application.

Worldwide Microalgae Market, By Geography Analysis: All of the areas and nations examined inside the report are concentrated on market size by item and application, central members, and market figure.

Profiles of International Players: Here, players are assessed on the possibility of their edge of benefit, value, deals, income, business, items, and other organization subtleties.

Market Dynamics: It incorporates store network examination, investigation of territorial promoting, difficulties, openings, and drivers dissected inside the report.

The study of disease transmission of the Research Study

Informative supplement: It incorporates insights concerning examination and philosophy approach, research strategy, information sources, creators of the investigation, and a disclaimer.

Note: If You Have Any Special Requirements, Please Let Us Know And We Will Offer You The Report As You Want. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Top Trending Reports:

Global CAR-T Therapy Treatment Market Trends, Competitive Landscape, Company Profiles And Forecast 2027 || Drugs-Yescarta, Kymriah, Actemra

Global Fitness App Market Growth At A Rate Of 21.30% In The Forecast Period Of 2020 To 2027 || Health Monitoring And Lifestyle Monitoring

Global Digital Therapeutic (DTx) Market Is Expected To Grow At 23.4% In The Forecast Period Of 2021 To 2028 || Cognoa Better Therapeutics, Inc CogniFit CANARY HEALTH Kaia Health

Global Psychedelic Drugs Market Growth With Worldwide Industry Analysis To 2027 Drugs-Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin | Players-Celon Pharma S.A. COMPASS F. Hoffmann-La Roche Ltd Hikma Pharmaceuticals PLC NeuroRx, Inc. PharmaTher Inc

Global EHealth Market Is Estimated To Reach Value Of USD 310.09 Billion By 2027 || IBM, Doximity, Inc., GE Healthcare, Cerner Corporation, Allscripts, McKesson Corporation, Koninklijke Philips

Global Physical Therapy Market Is Rising Exponentially At A CAGR Of 6.15% In The Forecast Period Of 2020 To 2027 ||Application- Orthopedic Physical Therapy, Geriatric Physical Therapy And Neurological Physical Therapy

U.S. Psychedelic Drugs Market Is Expected To Reach USD 6,859.95 Million By 2028 || Growth, Share, Demand And Analysis Of Key Players-Johnson & Johnson Services, Inc., Jazz Pharmaceuticals, Inc., Celon Pharma

Global Dog Food Market To USD 74.32 Billion By 2027 Growing At A CAGR Of 4.25% And Leading Key Players-General Mills Inc, Socit Des Produits Nestl S.A., Mars, ALPO and Blue Ridge

Why Go For Data Bridge Market Research?

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered to more than 40% of the fortune 500 companies ly and have a network of more than 5000+ clientele around the globe. Our coverage of industries includes: HEALTHCARE

ICT

FOOD & BEVERAGE

CHEMICAL & MATERIALS

SEMICONDUCTORS AND ELECTRONICS

AUTOMOTIVE

MATERIALS & PACKAGING

FMCG

AGRICULTURE & ANIMAL FEED

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: sales@databridgemarketresearch.com

Continued here:
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market : Industry Perspective, COVID-1 - PharmiWeb.com

SAKAI, Japan Just like humans, mans best friend deals with all sorts of chronic and degenerative conditions as they age. For dogs however, scientists have fewer ways of reversing life-threatening illnesses compared to human patients. Now, a team in Japan has successfully developed a technique which creates new stem cells from a dogs blood. Their study opens the door for new therapies which can regenerate a dogs body just like stem cells do in people.

In humans, these baby cells have the potential to grow into a variety of specialized cells, an ability called pluripotency. After scientists transplant these stem cells into a patient, they guide their differentiation into the specific kind of cells which completes their task. The new cells can then regenerate damaged tissues, reversing the effect of various diseases. While stem cell research for humans is a widely studied topic, researchers say little work is done with pets.

The new study, led by Associate Professor Shingo Hatoya from Osaka Prefecture University, focuses on induced pluripotent stem cells (iPSCs) in canine blood samples. Study authors say iPSCs are a type of stem cell which can be programmed from a developed cell. Scientists can do this by introducing specific genes into the cell. The genes code for specific proteins (transcription factors) which trigger the change from a developed cell into a pluripotent stem cell.

Another good thing about iPSCs is they multiply rapidly, providing a sustainable supply of usable stem cells for medical treatments.

We successfully established an efficient and easy generation method of canine iPSCs from peripheral blood mononuclear cells Dr. Hatoya in a university release.

The study authors call this a breakthrough in veterinary science. Hatoya hopes in the near future, it may be possible to perform regenerative medicinal treatments in dogs.

This isnt the first time scientists have experimented with iPSCs from canine blood cells. Researchers say these attempts used viral vectors to deliver the stem cell-triggering transcription factors.

In the new study, the Japanese team tested a different combination of factors to create pluripotency. Most importantly, researchers say they had to control how the reprogrammed cells multiplied in the host.

Scientists use viral vectors, which encode these transcription factors, to infect cells and convert them into iPSCs. Unfortunately, since these vectors merge with the hosts genetic material, these pluripotency factors can actually cause tumors if they are transplanted into a dog.

To avoid this, researchers created footprint-free stem cells using a special type of viral vector. This particular vector generates iPSCs without mixing with the hosts genes. It can also be automatically silenced by microRNAs in the cells. The OPU team grew these cells in a special environment which contained a small-molecule cocktail that enhances pluripotency. The results successfully produced cells which developed germ layers the basis of all organs.

Study authors say their findings provide a clear path to easy stem cell treatments for dogs. However, they add that their research may also have a ripple effect in the human medical world as well.

We believe that our method can facilitate the research involving disease modeling and regenerative therapies in the veterinary field, Dr. Hatoya says. Dogs share the same environment as humans and spontaneously develop the same diseases, particularly genetic diseases.

The team believes finding a cure for diseases in mans best friend may also open the door to curing illnesses still plaguing mankind.

The study appears in the journal Stem Cells and Development.

Read the original:
Breakthrough stem cell therapy may reverse life-threatening conditions in dogs - Study Finds

Dublin, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

Report scope

Stem Cell Partnering Terms and Agreements includes:

In Global Stem Cell Partnering Terms and Agreements 2010-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Stem Cell dealmaking2.1. Introduction2.2. Stem Cell partnering over the years2.3. Most active Stem Cell dealmakers2.4. Stem Cell partnering by deal type2.5. Stem Cell partnering by therapy area2.6. Deal terms for Stem Cell partnering2.6.1 Stem Cell partnering headline values2.6.2 Stem Cell deal upfront payments2.6.3 Stem Cell deal milestone payments2.6.4 Stem Cell royalty rates

Chapter 3 - Leading Stem Cell deals3.1. Introduction3.2. Top Stem Cell deals by value

Chapter 4 - Most active Stem Cell dealmakers4.1. Introduction4.2. Most active Stem Cell dealmakers4.3. Most active Stem Cell partnering company profiles

Chapter 5 - Stem Cell contracts dealmaking directory5.1. Introduction5.2. Stem Cell contracts dealmaking directory

Chapter 6 - Stem Cell dealmaking by technology type

Chapter 7 - Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/c8ppmy

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,...

Researchers at the Catholic University of Korea St. Marys Hospital have recently proved the efficacy of bone marrow-derived stem cells to treat ototoxicity hearing loss, the hospital said Thursday.

The team, led by Professor Park Kyoung-ho of the Department of Otolaryngology, conducted an experiment on animal models with ototoxic sensorineural hearing, or sudden hearing loss.

They utilized Catholic MASTER cells, bone marrow stem cells developed by the Catholic Institute of Cell Therapy, to compare the stem cell injection group with the controlled group.

The result showed that animals started to recover their hearing after three weeks. Five weeks later, they recovered normal hearing at 8000Hz, 16000Hz and 32000Hz frequency.

Ototoxic hearing loss is caused when a person ingests chemicals or certain medications that adversely affect the inner ear functions. Major symptoms related to the illness are dizziness, false hearing, and hearing loss, which permanently defects hearing functions. Elders with such symptoms should have medical consultations as they are a high-risk group, the hospital said.

We have proved the efficacy of our bone marrow stem cells in recovering hearing, said Professor Park, who doubles as the director of the Stem Cell Institute. Through the results, we expect to provide new treatment opportunities for patients with hearing loss.

The test results were published in the Korean Journal of Otorhinolaryngology-Head and Neck Surgery.

Read the original post:
Stem cells' efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review